Related Experiment Video

Updated: Jun 17, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

[Vaccination in paediatric oncohaematology]

Agnieszka Matkowska-Kocjan1, Alicja Chybicka

  • 1Katedra i Klinika Transplantacji Szpiku, Onkologii i Hematologii Dzieciecej, Akademii Medycznej we Wrocławiu, 50-345 Wrocław. a.matkowska@interia.pl

Medycyna Wieku Rozwojowego
|January 19, 2010
PubMed

Insights

Vaccination is crucial for children undergoing cancer treatment, especially after stem cell transplants. Modified vaccination schedules are essential for safely resuming immunizations post-therapy to protect these immunocompromised children.

Area of Science:

  • Pediatric Oncology
  • Immunology
  • Infectious Disease Prevention

Context:

  • Children with hematological malignancies and those undergoing chemotherapy or stem cell transplantation experience profound immunosuppression.
  • Anticancer therapies significantly impair immune system function, increasing susceptibility to infections.
  • The growing number of childhood cancer survivors highlights the importance of robust post-treatment health management, including vaccination.

Purpose:

  • To review and analyze current literature on vaccination strategies for children with a history of oncological diseases and immunosuppression.
  • To provide guidance on the safe and correct administration of vaccinations in immunocompromised pediatric patients post-chemotherapy or stem cell transplantation.
  • To address the complexities and variations in vaccination schedules across different countries and treatment centers.

Summary:

  • This article examines vaccination protocols for children after chemotherapy or stem cell transplantation, considering both obligatory and recommended antiviral and antibacterial vaccines.
  • It analyzes data from Polish and international literature, focusing on the temporary suspension and modified restart of immunizations during and after cancer treatment.
  • Key vaccines discussed include those for measles, mumps, rubella, polio, hepatitis B, influenza, varicella-zoster, human papillomavirus, diphtheria, tetanus, pertussis, Haemophilus influenzae b, meningococcal, pneumococcal, and tuberculosis.

Impact:

  • Informing clinical practice regarding safe and effective vaccination strategies for pediatric cancer survivors.
  • Contributing to the long-term health and well-being of children who have undergone intensive cancer treatments.
  • Highlighting areas of ongoing research and the need for standardized vaccination guidelines in pediatric oncology.

More Related Videos

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations01:51

Vaccinations

Overview
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...